The vote is 20-12 against withdrawing GSK’s troubled drug Avandia from the marketplace. Essentially, the FDA says that — in spite of the earlier vote the committee had on positively acknowledging the cardiac risks associated with the drug — those risks were not deemed strong enough to warrant removal. Twelve of the committee’s 33 members voted to pull Avandia off the market altogether, while only three supported leaving it on the market with its current labeling. Seven wanted to add stiffer language to the current label, and 10 wanted both stiffer language and restrictions on its use.

What is known now is that, according to the FDA, unless there is more long-term data on a link between Avandia’s use and cardiovascular death, there is nothing in terms of evidence currently convincing enough to warrant pulling the drug from the market. That’s the official statement by the agency, anyway.

Related Posts Within Doctor Pundit:

1. FDA Considers Ending Troubled GSK Drug’s Involvement in Safety Study Add yet another blow to GSK’s once-blockbuster diabetes drug, Avandia...
2. FDA to Decide Fate of Diabetes Drug This Week It’s official. The FDA will convene this Tuesday (13) to...
3. Report: Pharma Company Covered Up Known Cardiovascular Risks of Drug GSK (then known as SmithKline Beecham) knew in a 1999...
4. FDA Discussions on Avandia Enter 2nd Day As the debate over Avandia enters its second day, more...
5. FDA: Keep Avandia on Market, Impose Ponderous Restrictions on Use The FDA has announced today Avandia’s official indication. After months...